211 related articles for article (PubMed ID: 22445654)
1. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Pasero C; Speiser DE; Derré L; Olive D
Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
[TBL] [Abstract][Full Text] [Related]
2. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
3. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
5. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
6. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.
Steinberg MW; Cheung TC; Ware CF
Immunol Rev; 2011 Nov; 244(1):169-87. PubMed ID: 22017438
[TBL] [Abstract][Full Text] [Related]
7. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.
Pasero C; Truneh A; Olive D
Curr Mol Med; 2009 Sep; 9(7):911-27. PubMed ID: 19860669
[TBL] [Abstract][Full Text] [Related]
8. TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14).
Ware CF; Sedý JR
Curr Opin Immunol; 2011 Oct; 23(5):627-31. PubMed ID: 21920726
[TBL] [Abstract][Full Text] [Related]
9. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model.
Pierer M; Schulz A; Rossol M; Kendzia E; Kyburz D; Haentzschel H; Baerwald C; Wagner U
J Immunol; 2009 Mar; 182(5):3139-45. PubMed ID: 19234211
[TBL] [Abstract][Full Text] [Related]
10. A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production.
Pasero C; Barbarat B; Just-Landi S; Bernard A; Aurran-Schleinitz T; Rey J; Eldering E; Truneh A; Costello RT; Olive D
Eur J Immunol; 2009 Sep; 39(9):2502-14. PubMed ID: 19701890
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
[TBL] [Abstract][Full Text] [Related]
12. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
13. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
[TBL] [Abstract][Full Text] [Related]
14. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
15. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
16. Balancing co-stimulation and inhibition with BTLA and HVEM.
Murphy KM; Nelson CA; Sedý JR
Nat Rev Immunol; 2006 Sep; 6(9):671-81. PubMed ID: 16932752
[TBL] [Abstract][Full Text] [Related]
17. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
[TBL] [Abstract][Full Text] [Related]
18. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.
Chang YH; Hsieh SL; Chao Y; Chou YC; Lin WW
J Biomed Sci; 2005; 12(2):363-75. PubMed ID: 15917993
[TBL] [Abstract][Full Text] [Related]
19. Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.
Shrestha R; Garrett-Thomson SC; Liu W; Almo SC; Fiser A
Structure; 2020 Nov; 28(11):1197-1205.e2. PubMed ID: 32795404
[TBL] [Abstract][Full Text] [Related]
20. [Targeting TNF receptors in cancer therapy: toward a new role for LIGHT and HVEM].
Pasero C; Olive D
Bull Cancer; 2008; 95(7):691-700. PubMed ID: 18755648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
